Evolv Launches First Oral GLP-1 Biomimetic Pill
San Francisco, CA — Health startup Evolv has announced the launch of Evolv GLP-1, described as the world’s first oral GLP-1 pill. The biomimetic supplement was developed using genetic engineering and AI-driven molecular modeling to create a proprietary yeast strain that produces a novel peptide designed to activate the body’s own GLP-1 pathway.
Unlike prescription GLP-1 drugs, Evolv GLP-1 is positioned as a non-synthetic, non-habituating supplement aimed at supporting appetite control, metabolism, and long-term wellness without requiring injections or prescriptions. The company says its bioengineered EV1 Peptide molecule engages GLP-1 pathways in both the gut and brain to promote satiety, energy balance, and metabolic health.
Addressing Market Demand
GLP-1 drugs have surged in popularity in recent years, with prescriptions increasing more than 400% in the U.S. However, accessibility remains a challenge: many adults report difficulty affording treatments, while some experience adverse side effects. Evolv aims to offer an alternative through a consumer supplement that leverages biomimetic science rather than pharmaceuticals.
“By engineering food-safe yeast as a scalable delivery system for complex biomimetic molecules, we see a path for translating therapeutic-grade science into everyday health tools,” said Dr. Cory Henderson, co-founder of Evolv.
A New Approach to Biomimetics
Evolv’s debut is part of the company’s broader effort to apply therapeutic-grade molecular engineering to consumer health. By using yeast as a delivery system for engineered peptides, Evolv says it can create shelf-stable, bioavailable supplements that mirror hormone activity without introducing synthetic compounds.
The company sees potential applications beyond weight management, with biomimetic supplements offering new approaches to metabolic health, longevity, and wellness. Evolv positions this model as a blueprint for expanding access to advanced biologics outside traditional clinical settings.
